EUDA Health raises $3.75M, cancels share warrant

EUDA Health Holdings Limited completed a registered offering of 12,500,000 ordinary shares for an aggregate purchase price of $3,750,000, using its Form F-3 shelf registration and a March 2026 prospectus supplement.

Rhea-AI Filing Summary

EUDA Health Holdings Limited completed a registered offering of 12,500,000 ordinary shares for an aggregate purchase price of $3,750,000, using its Form F-3 shelf registration and a March 2026 prospectus supplement. The company plans to use the net proceeds for general corporate purposes, including possible acquisitions, business expansion and working capital.

Separately, EUDA repurchased in full a previously issued warrant that was exercisable for 2,000,000 newly issued ordinary shares, paying $125,000 on February 27, 2026, and the warrant was cancelled. The report also incorporates this information by reference into the company’s existing Form F-3 registration statement.

Insights

Capital markets analyst

EUDA raises $3.75M via share sale and removes a 2,000,000-share warrant overhang.

EUDA Health completed a registered offering of 12,500,000 ordinary shares for $3,750,000. The transaction uses an existing Form F-3 shelf, allowing the company to access public capital while directing proceeds to general corporate purposes, including potential acquisitions, expansion initiatives and working capital needs.

The company also repurchased and cancelled a warrant that had been immediately exercisable into 2,000,000 shares, paying $125,000 on February 27, 2026. Removing this warrant eliminates a defined source of future share issuance. Overall effects on valuation will depend on how effectively new capital is deployed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What capital did EUDA (EUDA) raise in the March 2026 offering?

EUDA Health raised gross proceeds of $3,750,000 by selling 12,500,000 ordinary shares. The shares were issued under its existing Form F-3 shelf, using a prospectus dated November 4, 2024 and a March 2, 2026 prospectus supplement.

How will EUDA Health (EUDA) use the $3,750,000 raised?

EUDA intends to use the net proceeds for general corporate purposes. This includes possible acquisitions, expansion of its business and additional working capital, giving the company flexibility to fund growth initiatives and support ongoing operations as opportunities arise.

What happened to EUDA’s warrant for 2,000,000 ordinary shares?

EUDA repurchased the warrant, which was exercisable into 2,000,000 newly issued ordinary shares, for $125,000 on February 27, 2026. After this transaction, the warrant was cancelled, removing that specific potential source of future share issuance.

Under which registration statement did EUDA conduct the March 2026 share sale?

The March 2026 share sale was conducted under EUDA’s Form F-3 registration statement, File No. 333-282723. A prospectus dated November 4, 2024 and a March 2, 2026 prospectus supplement governed the issuance of the 12,500,000 ordinary shares.

Who purchased the shares in EUDA Health’s March 2026 offering?

The shares were sold to accredited investors under Securities Purchase Agreements dated on or about February 24 and 25, 2026. These investors agreed to buy an aggregate of 12,500,000 ordinary shares for a total purchase price of $3,750,000.

Does the EUDA (EUDA) Form 6-K itself constitute an offer to sell shares?

No. The Form 6-K explicitly states it does not constitute an offer to sell or a solicitation to buy ordinary shares in any jurisdiction where such activity would be unlawful before proper registration or qualification under applicable securities laws.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 08:30 AM EST Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February, 2026

Commission File Number: 001-40678

EUDA Health Holdings Limited

(Exact Name of Registrant as Specified in its Charter)

60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: +65 6327 1110

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

EUDA Health Holdings Limited (“EUDA” or the “Company”) entered into certain Securities Purchase Agreements (the “Securities Purchase Agreements”), dated on or about February 24 and 25, 2026, by and between the Company and the accredited investors named therein for the purchase of an aggregate of 12,500,000 ordinary shares for an aggregate purchase price of $3,750,000 (the “March 2026 Offering”). The ordinary shares were issued and sold pursuant to the Company’s prospectus dated November 4, 2024 and a prospectus supplement dated March 2, 2026 (the “Prospectus Supplement”). The Prospectus Supplement forms a part of the Company’s Registration Statement on Form F-3 (File No. 333-282723), which was filed with the Securities and Exchange Commission on October 18, 2024, as amended on October 30, 2024, and declared effective on November 4, 2024. The Company intends to use the net proceeds from the March 2026 Offering for general corporate purposes, including possible acquisitions or the expansion of its business and working capital.

As previously disclosed, the Company entered into a securities purchase agreement dated as of November 26, 2025 with an accredited investor (the “Purchaser”) for the purchase of a warrant that was immediately exercisable into 2,000,000 newly-issued ordinary shares (the “Warrant”). As previously disclosed, the Warrant was previously amended on each of December 16, 2025 and January 13, 2026. On February 27, 2026, the Company repurchased the Warrant in full for the purchase price of $125,000, and the Warrant was cancelled.

The foregoing description of the Securities Purchase Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of the form of Securities Purchase Agreement, a copy of which is filed as Exhibit 1.1 this Current Report, and incorporated by reference herein.

This Report on Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy the ordinary shares nor shall there be any sale of the ordinary shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

This Report on Form 6-K is incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-282723) and the prospectus thereof and any prospectus supplements or amendments thereto.

Exhibits

1.1		Form of Securities Purchase Agreement
5.1		Opinion of Conyers Dill & Pearman Pte. Ltd.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dated: March 2, 2026
EUDA Health Holdings Limited
By:	/s/ Alfred Lim
	Alfred Lim
	Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-1.1 EX-1.1 107.6 KB
• EX-5.1 EX-5.1 69.4 KB
• EX-5 GRAPHIC 14.7 KB